- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Omega-3 and vitamin D supplements tied with lesser hospitalizations in HF patients

A study published in JACC: Heart Failure suggested that patients with and without type 2 diabetes who took omega-3 and vitamin D supplements were less likely to be hospitalized for heart failure, compared with those who took placebos.
The primary aim was to evaluate whether prevalent type 2 diabetes (T2D) modifies the effects of omega-3 supplementation on heart failure (HF) hospitalization. The secondary aim was to examine if race modifies the effects of omega-3 supplements on heart failure (HF) risk.
It is unclear whether race and type 2 diabetes (T2D) modify the effects of omega-3 supplementation on the incidence of HF. In this ancillary study of the parent VITAL (Vitamin D and Omega-3 Trial)—a completed randomized trial testing the efficacy of vitamin D and omega-3 fatty acids on cardiovascular diseases and cancer, we assessed the role of type 2 diabetes (T2D) and race on the effects of omega-3 supplements on the incidence of heart failure (HF) hospitalization (adjudicated by a review of medical records and supplemented with a query of Centers for Medicare and Medicaid Services data).
The results of the study are:
- When omega-3 supplements were compared with placebo, the HR for first HF hospitalization was 0.69 in participants with prevalent type 2 diabetes (T2D) and 1.09 in those without type 2 diabetes (T2D)
- Furthermore, prevalent type 2 diabetes (T2D) modified the effects of omega-3 fatty acids on the incidence of recurrent heart failure (HF) hospitalization
- In their secondary analysis, omega-3 supplementation reduced recurrent heart failure hospitalization only in Black participants
Thus, the data show beneficial effects of omega-3 fatty acid supplements on the incidence of heart failure (HF) hospitalization in participants with type 2 diabetes (T2D) but not in those without type 2 diabetes (T2D), and such benefit appeared to be stronger in Black participants with type 2 diabetes (T2D).
Reference:
Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization by Luc Djoussé et. al published in the JACC: Heart Failure.
https://www.sciencedirect.com/science/article/abs/pii/S2213177922000543?via=ihub
BDS
Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.